

- 2 **Jak snížit kardiovaskulární riziko nově diagnostikovaného hypertonika**  
MUDr. Eva Kociánová I. interní klinika – kardiologická, FN, Olomouc
- 2 **Praktické využití fixní kombinace perindopril/indapamid u staršího pacienta ve vysokém kardiovaskulárním riziku**  
MUDr. Petr Razák Kardiologie na Bulovce, s. r. o., Praha
- 2 **Alirocumab u pacientů s familiární hypercholesterolemií**  
prof. MUDr. Vladimír Bláha, CSc. III. interní gerontometabolická klinika LF UK a FN, Hradec Králové
- 3 **Afinitor (everolimus) ve vyšší linii léčby metastatického renálního karcinomu**  
MUDr. Hana Korunková Onkologická a radioterapeutická klinika FN, Plzeň
- 3 **Avastin s paklitaxelem u pacientky s triple negativním karcinomem prsu**  
MUDr. Ivana Bustová Onkologické oddělení, Nemocnice České Budějovice, a. s.
- 3 **Léčba Avastinem u pacienta s NSCLC**  
MUDr. Lenka Jakubíková, Ph.D. | MUDr. Jana Špeldová | MUDr. Ondřej Venclíček |  
prof. MUDr. Jana Skříčková, CSc. Klinika nemocí plicních a tuberkulózy FN, Brno
- 3 **Metastatický a inoperabilní bazocelulární karcinom léčený vismodegibem**  
MUDr. David Šulc | MUDr. Denisa Šmejkalová Onkologické oddělení, Krajská zdravotní, Masarykova nemocnice, Ústí nad Labem
- 3 **Léčba ALK inhibítorem – Xalkori**  
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha
- 4 **Léčba starší nemocné s chronickou lymfocytární leukemií kombinací obinutuzumab a chlorambucil**  
MUDr. Jana Zuchnická | MUDr. Jana Fečková Mihályová Klinika hematooonkologie FN, Ostrava  
prof. MUDr. Roman Hájek, CSc. Klinika hematooonkologie FN, Ostrava, LF Ostravské univerzity, Ostrava
- 4 **GOLD 2017: novinky v léčbě CHOPN**  
MUDr. Eva Voláková Klinika plicních nemocí a tuberkulózy, FN, Olomouc
- 4 **Hyperandrogenní stavy v gynekologii**  
MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha
- 4 **Manažersky dokonalá erekce**  
MUDr. Lukáš Bittner, FEBU, FECSM Urologická klinika 3. LF UK a FNKV, Praha
- 5 **Jednostranné postižení tonzily nejasné etiologie**  
MUDr. David Jilich Klinika infekčních, parazitárních a tropických nemocí Nemocnice na Bulovce, Praha
- 5 **Atypický průběh Gaucherovy choroby**  
MUDr. Věra Malinová Klinika dětského a dorostového lékařství VFN a 1. LF UK, Praha
- 5 **Gravidita po čtyřech měsících od prvního podání alemtuzumabu**  
MUDr. Petra Lišková | MUDr. Eva Meluzínová Neurologická klinika 2. LF UK a FN Motol, Praha

# Jak snížit kardiovaskulární riziko nově diagnostikovaného hypertonika

MUDr. Eva Kociánová I. interní klinika – kardiologická, FN, Olomouc

- 1 Neaton, J. D. – Wentworth, D.: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. *Arch Intern Med*, 1992, 152, s. 56–64.
- 2 World Health Organization. Global atlas on cardiovascular disease prevention and control. Dostupné z: [www.world-heart-federation.org/fileadmin/user\\_upload/images/CVD\\_Health/Global\\_CVD\\_Atlas.pdf](http://www.world-heart-federation.org/fileadmin/user_upload/images/CVD_Health/Global_CVD_Atlas.pdf), vyhledáno 23. 2. 2015.
- 3 Authors/Task Force Members: Lancia, G. – Fagard, R. – Narkiewicz, R., et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension. *European Heart Journal*, 2013, 34, s. 2159–2219.
- 4 Bakris, G. – Briasoulis, A. – Dahlof, B., et al.: ACCOMPLISH Investigators. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. *Am J Cardiol*, 2013, 112, s. 255–259.
- 5 Filipovský, J. – Widimský, J. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Hypertenze & kardiovaskulární prevence*, 2012, 3, s. 1–16.
- 6 Authors/Task Force Members: Piepoli, M. F. – Hoes, A. W. – Agewall, S., et al.: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Atherosclerosis*, 2016, 252, s. 207–274.
- 7 Conroy, R. M. – Pyörälä, K. – Fitzgerald, A. P., et al.: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE Project. *Eur Heart J*, 2003, 11, s. 987–1003.
- 8 Cífková, R. – Býma, S. – Češka, R., et al.: Prevence kardiovaskulárních onemocnění v dospělém věku. *Cor Vasa*, 2005, 47, s. 3–14.
- 9 2016 ESC/EAS Guidelines for the Management of Dyslipidemia. Šéfredaktor Thomas F. Lüscher, *European Heart Journal*. DOI: <http://dx.doi.org/10.1093/eurheartj/ehw272> ehw272, publikováno online 27. 8. 2016.
- 10 Chapman, R. H. – Banner, J. S. – Petrilla, A. A., et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. *Arch Intern Med*, 2005, 165, s. 1147–1152.
- 11 Poulter, N. R. – Prabhakaran, D. – Caulfield, M.: Hypertension. *Lancet*, 2015, 386, s. 801–812, doi: 10.1016/S0140-6736(14)61468-1469. Review.
- 12 Jackson, R. – Lawes, C. M. – Bennett, D. A., et al.: Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. *Lancet*, 2005, 365, s. 434–441.

## Praktické využití fixní kombinace perindopril/indapamid u staršího pacienta ve vysokém kardiovaskulárním riziku

MUDr. Petr Razák Kardiologie na Bulovce, s. r. o., Praha

- 1 Dostupné z: <http://www.uzis.cz/cr-kraje>, vyhledáno 29. 11. 2016.
- 2 Lancia, G. – De Backer, G. – Dominiczak, A., et al.: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. *J Hypertens*, 2007, 25, s. 1105–1187.
- 3 Filipovský, J. – Widimský, J. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Vnitř Lék*, 2012, 58, s. 785–801.
- 4 Pella, D.: Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5mg. Results of the FALCO FORTE programme. *High Blood Press Cardiovasc Prev*, 2011, 18, s. 107–113.
- 5 Progress Collaborative Group: Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet*, 2001, 358, s. 1033–1041.
- 6 Arima, H. – Chalmers, J. – Woodward, M., et al.: PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. *J Hypertens*, 2006, 24, s. 1201–1208.
- 7 Yusuf, S. – Diener, H. C. – Sacco, R. L., et al.: Telmisartan to prevent recurrent stroke and cardiovascular events. *NEJM*, 2008, 359, s. 1225–1237.
- 8 Van Vark, L. C. – Bertrand, M. – Akkerhuis, K. M., et al.: Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomised clinical trials of RAAS inhibitors involving 158 998 patients. *Eur Heart J*, 2012, 33, s. 2088–2097.
- 9 Brugts, J. J. – van Vark, L. – Akkerhuis, M., et al.: Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis. *Int J Cardiol*, 2015, 181, s. 425–429.
- 10 Bangalore, S. – Fakheri, R. – Toklu, B., et al.: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254 301 patients from randomized trials. *Mayo Clin Proc*, 2016, 91, s. 51–60.
- 11 Ferrari, R. – Boersma, E.: The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials. *Expert Rev Cardiovasc Ther*, 2013, 11, s. 705–717.
- 12 Savarese, G. – Costanzo, P. – Cleland, J. G., et al.: A meta-analysis reporting effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. *J Am Coll Cardiol*, 2013, 61, s. 131–142.

## Alirocumab u pacientů s familiární hypercholesterolemií

prof. MUDr. Vladimír Bláha, CSc. III. interní gerontometabolická klinika LF UK a FN, Hradec Králové

- 1 Navarese, E. P. – Kolodziejczak, M., et al.: Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. *Ann Intern Med*, 2015, 163, s. 40.
- 2 Zhang, X. L. – Zhu, Q. Q. – Zhu, L., et al.: Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. *BMC Med*, 2015, 13, s. 123.
- 3 Sattar, N. – Preiss, D. – Robinson, J. G., et al.: Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Publikováno online před tiskem 8. 2. 2016, *Lancet Diabetes Endocrinol*, doi:10.1016/S2213-8587(16)00003-6.
- 4 Ricotta, D. N. – Frishman, W. H.: Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. *Cardiol in Rev*, 2012, 20, s. 90–95.
- 5 Reiner, Z.: Management of patients with familial hypercholesterolemia. *Nat Rev Cardiol*, 2015, 12, s. 565–575.
- 6 Kastelein, J. J. P. – Ginsberg, H. N. – Langslet, G., et al.: ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia. *Eur Heart J*, 2015, doi: <http://dx.doi.org/10.1093/eurheartj/ehv370>.
- 7 Roth, E. M. – McKenney, J. M.: ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. *Future Cardiol*, 2015, 11, s. 27–37.
- 8 Kereiakes, D. J. – Robinson, J. G., et al.: Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. *Am Heart J*, 2015, 169, s. 906–915, e13.
- 9 Canon, C. P. – Cariou, B. – Blom, D., et al.: Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. *Eur Heart J*, 2015, 36, s. 1186–1194.
- 10 Bays, H. – Gaudet, D. – Weiss, R., et al.: Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. *J Clin Endocrinol Metab*, 2015, 100, s. 3140–3148.
- 11 Bays, H. – Farnier, M. – Gaudet, D., et al.: Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II. Dostupné z: [https://professional.heart.org/idc/groups/ahamh-public/@wcm/@sop/@scon/documents/downloadable/ucm\\_469615.pdf](https://professional.heart.org/idc/groups/ahamh-public/@wcm/@sop/@scon/documents/downloadable/ucm_469615.pdf), vyhledáno 28. 11. 2016.
- 12 Lipinami, M. J. – Benedetto, U. – Escarcega, R. O., et al.: The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolemia: a network meta-analysis. *Eur Heart J*, 2015, doi: <http://dx.doi.org/10.1093/eurheartj/ehv563>.
- 13 Sanofi/Regeneron. ODYSSEY Outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727). ClinicalTrials.gov [database online]. Bethesda (MD): National Library of Medicine (US). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01663402>, vyhledáno 28. 11. 2016.
- 14 Tice, J. A. – Ollendorf, D. A. – Cunningham, C., et al.: PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks draft report. Institute for Clinical and Economic Review (ICER), 8. 9. 2015. Dostupné z: <https://icer-review.org/wp-content/uploads/2016/01/Final-Report-for-Posting-11-24-15-1.pdf>, vyhledáno 28. 11. 2016.
- 15 Robinson, J. G. – Farnier, M. – Krempf, M., et al.: Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 2015, 372, s. 1489–1499, <http://dx.doi.org/10.1056/NEJMoa1501031>.
- 16 Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. Dostupné z: <http://www.pfizer.com/news/press-release/press-release-detail/>

přerušování globálního rozvoje bocicizumabu, výhledová studie, vyhodnoceno 28. 11. 2016.

17 **Stein, E. A. – Sampietro, T. – Santos, R., et al.:** Long-term treatment with evolocumab homozygous familial hypercholesterolemia

patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSI). Kongres European Atherosclerosis Society, 31. 5. 2016, Innsbruck, Rakousko, abstrakt 146.

18 **Moriarty, P. M. – Parhofer, K. G. – Baborák, S. P., et al.:** Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. *Eur Heart J*, 2016, 0, s. 1–8, doi:10.1093/eurheartj/ehw388.

## Afinitor (everolimus) ve vyšší linii léčby metastatického renálního karcinomu

MUDr. Hana Korunková Onkologická a radioterapeutická klinika FN, Plzeň

1 **Procopio, G. – Verzoni, E. – Iacovelli, R., et al.:** Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients. 2012 ASCO Annual Meeting. Citace: *J Clin Oncol*, 2012, 30, abstrakt 4629.

## Avastin s paklitaxelem u pacientky s triple negativním karcinomem prsu

MUDr. Ivana Bustová Onkologické oddělení, Nemocnice České Budějovice, a. s.

1 **Kümler, I. – Christiansen, O. G. – Nielsen, D. L.:** A systematic review of bevacizumab efficacy in breast cancer. *Cancer Treat Rev*, 2014, 40, s. 960–973.

2 **Gligorov, J. – Doval, D. – Bines, J. et al.:** Maintenance capecitabine

and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open label, phase 3 trial. *Lancet Oncol*, 2014, 15, s. 1351–1360.

3 Adaptováno z: **Delaloge, S., et al.:** Results of a multicenter national observational study. *J Clin Oncol*, 2016, 34, abstrakt 1013, ASCO 2016.

## Léčba Avastinem u pacienta s NSCLC

MUDr. Lenka Jakubíková, Ph.D. | MUDr. Jana Špeldová | MUDr. Ondřej Venclíček | prof. MUDr. Jana Skříčková, CSc. Klinika nemocí plicních a tuberkulózy FN, Brno

1 **Sandler, A. – Gray, R. – Perry, M. C., et al.:** Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer *MD N Engl J Med*, 2006, 355, s. 2542–2550.

2 **Reck, M. – von Pawel, J. – Zatloukal, P., et al.:** Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line

therapy for non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 27, s. 1227–1234.

3 **Takashi, S., et al.:** Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (J025567): an open-label,

randomised, multicentre phase 2 study. *Lancet Oncology*, 2014, 15, s. 1236–1244.

4 **Skříčková, J. – Kolek, V., et al.:** *Základy moderní pneumonologie*. Maxdorf, Praha, 2012.

## Metastatický a inoperabilní bazocelulární karcinom léčený vismodegibem

MUDr. David Šulc | MUDr. Denisa Šmejkalová  
Onkologické oddělení, Krajská zdravotní, Masarykova nemocnice, Ústí nad Labem

1 **Lear, J. T. – Harvey, I. – de Berker, D. – Strange, R. C. – Fryer, A. A.:** Basal cell carcinoma. *J R Soc Med*, 1998, 91, s. 585–588.

2 **Roewert-Huber, J. – Lange-Asschenfeldt, B. – Stockfleth, E. – Kerl, H.:** Epidemiology and aetiology of basal cell carcinoma.

*Br J Dermatol*, 2007, 157, s. 47–51.

3 **Von Hoff, D. D. – LoRusso, P. M. – Rudin, C. M., et al.:** Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med*, 2009, 361, s. 1164–1172.

4 **Sekulic, A., et al.:** Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Engl J Med*, 2012, 366, s. 2171–2179.

## Léčba ALK inhibítorem – Xalkori

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha

1 **Klak, E. L. – Bang, Y. – Camidge, D. R., et al.:** Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*, 2010, 363, s. 1693–1703.

2 **Camidge, D. R. – Bang, Y. – J. Kwak, E. L., et al.:** Activity and safety

of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncol*, 2012, 13, s. 1011–1019.

3 **Shaw, A. T. – Kim, D. W. – Nakagawa, K., et al.:** on behalf of all PROFILE

1007 investigators: Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC. Prezentováno na 37. kongresu ESMO Congress, Vídeň, Rakousko, 2012, abstrakt LBA1 PR.

- Solomon, B. J. – Mok, T. – Kim, D. W., et al.: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*, 2014, 371, s. 2167–2177.
- Mok, T. – Kim, D. W. – Solomon, B. J., et al.: First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). *J Clin Oncol*, 2014, 32, abstrakt 8002.
- Ou, S. H. – Jänne, P. A. – Bartlett, C. H., et al.: Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. *Ann Oncol*, 2014, 25, s. 415–422.
- Costa, D. B. – Shaw, A. T. – Ou, S. H., et al.: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastase. *J Clin Oncol*, 2015, 33, s. 1881–1888.
- Cappuzzo, F. – Moro-Sibilot, D. – Gautschi, O., et al.: Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. *Lung Cancer*, 2015, 87, s. 89–95.
- Shaw, A.: Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med*, 2015, 372, s. 683–684.
- Kris, M. G. – Johnson, B. E. – Kwiatkowski, D. J., et al.: Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). 2011 ASCO Annual Meeting. *J Clin Oncol*, 2011, 29, dopl., abstrakt CRA7506.
- Costa, D. B. – Shaw, A. T. – Ou, S. H. – Salomon, B. J., et al.: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. *J Clin Oncol*, 2015, 33, s. 1881–1888.
- Solomon, B. J. – Mok, T. – Kim, D. W., et al.: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*, 2014, 371, s. 2167–2177.

## Léčba starší nemocné s chronickou lymfocytární leukemií kombinací obinutuzumab a chlorambucil

MUDr. Jana Zuchnická | MUDr. Jana Fečková Mihályová Klinika hematologie FN, Ostrava  
prof. MUDr. Roman Hájek, CSc. Klinika hematologie FN, Ostrava, LF Ostravské univerzity, Ostrava

- Herting, F. – Friess, T. – Bader, S., et al.: Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. *Leuk Lymphoma*, 2014, 55, s. 2151–2160.
- Cartron, G. – de Guibert, S. – Dillhuydy, M. S., et al.: Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. *Blood*, 2014, 124, s. 2196–2202.
- Salvi, F. – Miller, M. D. – Grilli, A., et al.: A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. *J Am Geriatr Soc*, 2008, 56, s. 1926–1931.
- Goede, V. – Fischer, K. – Engelse, A., et al.: Obinutuzumab as front-line treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study. *Leukemia*, 2015, 29, s. 1602–1604.
- Goede, V. – Fischer, K. – Busch, R., et al.: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*, 2014, 370, s. 1101–1110.
- Moreau, E. J. – Matutes, E. – A'Hern, R. P., et al.: Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). *Am J Clin Pathol*, 1997, 108, s. 378–382.
- Binet, J. L. – Auquier, A. – Dighiero, G., et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. *Cancer*, 1981, 48, s. 198–206.
- Rai, K. R. – Sawitsky, A. – Cronkite, E. P., et al.: Clinical staging of chronic lymphocytic leukemia. *Blood*, 1975, 46, s. 219–234.
- Hallek, M. – Cheson, B. D. – Katovsky, D., et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood*, 2008, 111, s. 5446–5456.
- Smolej, L., et al.: Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie (CLL). Česká skupina pro chronickou lymfocytární leukemii, sekce České hematologické společnosti České lékařské společnosti Jana Evangelisty Purkyně (ČHS ČLS JEP), 9. 5. 2016, schváleno výběrem ČHS ČLS JEP.

## GOLD 2017: novinky v léčbě CHOPN

MUDr. Eva Voláková Klinika plicních nemocí a tuberkulózy, FN, Olomouc

- GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. Dostupné z: [goldcopd.org](http://goldcopd.org).
- Cazzola, M. – Page, C. P. – Calzetta, L., et al.: Pharmacology and therapeutics of bronchodilators. *Pharm Reviews*, 2012, 64, s. 450–504.
- Agusti, A., et al.: prezentace na kongresu ERS 2011.
- Cheer, S. M. – Scott, L. J.: Formoterol. A review of its use in chronic obstructive pulmonary disease. *Am J Respir Med*, 2002, 1, s. 285–300.
- Bateman, E. D. – Chapman, K. R. – Singh, D., et al.: Acilidium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). *Respiratory Research*, 2015, 16, s. 92 – souhrnné studie.

## Hyperandrogenní stavy v gynekologii

MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha

- Cordain, L. – Lindeberg, S. – Hurtado, M., et al.: Acne vulgaris: a disease of western civilization. *Arch Dermatol*, 2002, 138, s. 1584–1590.
- Thiboutot, D. – Martin, P. – Volikos, L., et al.: Oxidative activity of the type 2 isozyme of 17β-Hydroxysteroid dehydrogenase (17β-HSD) predominates in human sebaceous glands. *J Invest Dermatol*, 1998, 111, s. 390–395.
- O'Connell, K. – Westhoff, C.: Pharmacology of hormonal contraceptives and acne. *Cutis*, 2008, 81, s. 8–12.
- Ferriman, D. – Gallwey, J. D.: Clinical assessment of body hair growth in women. *J Clin Endocrinol Metab*, 1961, 21, s. 1440.
- Azziz, R. – Carmina, E. – Dewailly, D., et al.: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertil Steril*, 2009, 91, s. 456–488.
- Goodarzi, M. O. – Dumesic, D. A. – Chazenbalk, G., et al.: Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. *Nat Rev Endocrinol*, 2011, 7, s. 219–231.
- Spritzer, P. – Billaud, L. – Thalabard, J. C., et al.: Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. *J Clin Endocrinol Metab*, 1990, 70, s. 642.
- Birnbaum, M. D. – Rose, L. I.: The partial adrenocortical hydroxylase deficiency syndrome in infertile women. *Fertil Steril*, 1979, 32, s. 536.
- Carmina, E. – Roseto, F. – Janni, A., et al.: Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. *J Clin Endocrinol Metab*, 2006, 91, s. 2.
- Goldman, J. M. – Kapadia, L. J.: Virilization in a postmenopausal woman due to ovarian stromal hyperthecosis. *Postgrad Med J*, 1991, 67, s. 304.
- Nagamani, M. – Lingold, J. C. – Gomez, L. G., et al.: Clinical and hormonal studies in hyperthecosis of the ovaries. *Fertil Steril*, 1981, 36, s. 326.

## Manažersky dokonalá erekce

MUDr. Lukáš Bittner, FEBU, FECSM Urologická klinika 3. LF UK a FNKV, Praha

- Cui, Y. S. – Li, N. – Zong, H. T., et al.: Avanafil for male erectile dysfunction: a systematic review and meta-analysis. *Asian J Androl*, 2014, 16, s. 472 – 477.

# Jednostranné postižení tonzily nejasné etiologie

MUDr. David Jilich

Klinika infekčních, parazitárních a tropických nemocí Nemocnice na Bulovce, Praha

- 1 Dostupné z: <https://hivbook.com/category/part-3-aids/12-kaposis-sarcoma/>, vyhledáno 5. 12. 2016.
- 2 Vaňousová, D. – Jilich, D. – Machala, L., et al.: Diagnostic pitfalls of HIV-associated Kaposi's sarcoma. *Klin Onkol*, 2010, 23, s. 285–292.
- 3 Clotet, B., et al.: *Lancet*, 2015, 385, s. 2576.
- 4 Hasan, S. – Jamdar, S. F. – Langra, J., et al.: Oral malignant melanoma: An aggressive clinical entity – Report of a rare case with review of literature. *J Int Soc Prev Community Dent*, 2016, 6, s. 176–181.
- 5 Beneš, J.: *Infekční lékařství*. Galén, Praha, 2009.

# Atypický průběh Gaucherovy choroby

MUDr. Věra Malinová Klinika dětského a dorostového lékařství VFN a 1. LF UK, Praha

- 1 Burrow, A. T. – Sun, Y. – Prada, C. E., et al.: CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathological, and biochemical findings. *Mol Genet Metab*, 2015, 114, s. 233–241, doi 10.1016/j.ymge.2014.08.011.
- 2 Yagci, B. – Saor, Ö. – Yalcin, B., et al.: *Giant lymphadenopathy infiltrated by Gaucher cells mimicking lymphoma*. Wiley-Liss, Inc., 2009, doi 10.1002/pbc.21948.
- 3 Sherwani, P. – Vire, A. – Nand, R. – Gusta, R.: Lung lysed: A case of Gaucher disease with pulmonary involvement. *Lung India*, 2016, 33, s. 108–110.

# Gravidita po čtyřech měsících od prvního podání alemtuzumabu

MUDr. Petra Lišková | MUDr. Eva Meluzínová Neurologická klinika 2. LF UK a FN Motol, Praha

- 1 De Giglio, L. – Gasperini, C. – Tortorella, C., et al.: Natalizumab discontinuation and disease restart in pregnancy: a case series. *Acta Neurol Scand*, 2015, 131, s. 336–340.
- 2 Hartung, H. P. – Aktas, O. – Boyko, A. N.: Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. *Mult Scler*, 2015, 21, s. 22–34.
- 3 Havrdova, E. – Horakova, D. – Kovarova, I.: Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. *Ther Adv Neurol Disord*, 2015, 8, s. 31–45.
- 4 Jones, J. L. – Anderson, J. M. – Phuah, C. L., et al.: Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. *Brain*, 2010, 133, s. 2232–2247.
- 5 Meluzínová, E.: Alemtuzumab v léčbě roztroušené sklerózy. *Neurol Prax*, 2015, 16, s. 237–240.
- 6 Rau, D. – Lang, M. – Harth, A., et al.: Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis-report of two cases. *Int J Mol Sci*, 2015, 16, s. 14669–14676.
- 7 Ruck, T. – Bittner, S. – Wiendl, H., et al.: Alemtuzumab in multiple sclerosis: mechanism of action and beyond. *Int J Mol Sci*, 2015, 16, s. 16414–16439.
- 8 Achiron, A. – Chambers, Ch. – Fox, E. J., et al.: Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program. 31<sup>st</sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 7.–10. 10. 2015, Barcelona, Španělsko, P1120.